Anagliptin twice‐daily regimen improves glycaemic variability in subjects with type 2 diabetes: A d <scp>ouble‐blind</scp> , randomized controlled trial-Reference-Cited by-同舟云学术

Anagliptin twice‐daily regimen improves glycaemic variability in subjects with type 2 diabetes: A d ouble‐blind , randomized controlled trial

Published:2023-01-10 Issue:5 Volume:25 Page:1174-1185
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Lee Yong‐ho¹^ORCID,Kim Doo‐Man²^ORCID,Yu Jae Myung³,Choi Kyung Mook⁴^ORCID,Kim Sin Gon⁵^ORCID,Park Kang Seo⁶,Son Hyun‐Shik⁷,Chung Choon Hee⁸^ORCID,Ahn Kyu Jeung⁹,Lee Soon Hee¹⁰,Song Ki‐Ho¹¹,Kwon Su Kyoung¹²,Park Hyeong Kyu¹³,Won Kyu Chang¹⁴,Jang Hak Chul¹⁵^ORCID,

Affiliation:

1. Department of Internal Medicine Yonsei University College of Medicine Seoul South Korea

2. Department of Internal Medicine, Hallym University Kangdong Sacred Heart Hospital Hallym University College of Medicine Seoul South Korea

3. Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital Hallym University College of Medicine Seoul South Korea

4. Division of Endocrinology and Metabolism, Department of Internal Medicine Korea University Guro Hospital, Korea University College of Medicine Seoul South Korea

5. Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine Korea University Seoul South Korea

6. Division of Endocrinology and Metabolism, Department of Internal Medicine, Daejeon Eulji Medical Center Eulji University School of Medicine Daejeon South Korea

7. Division of Endocrinology and Metabolism, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine The Catholic University of Korea Seoul South Korea

8. Division of Endocrinology and Metabolism, Department of Internal Medicine, Wonju Severance Christian Hospital Yonsei University Wonju College of Medicine Wonju South Korea

9. Department of Endocrinology and Metabolism Kyung Hee University School of Medicine Seoul South Korea

10. Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine Inje University Busan South Korea

11. Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine The Catholic University of Korea Seoul South Korea

12. Department of Endocrinology Kosin University Gospel Hospital, Kosin University College of Medicine Busan South Korea

13. Division of Endocrinology and Metabolism, Department of Internal Medicine Soonchunhyang University Hospital, Soonchunhyang University College of Medicine Seoul South Korea

14. Department of Internal Medicine Yeungnam University College of Medicine Daegu South Korea

15. Department of Internal Medicine Seoul National University Bundang Hospital Seongnam South Korea

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14959

Reference42 articles.

1. 2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association

2. Postchallenge Hyperglycemia in a National Sample of U.S. Adults With Type 2 Diabetes

3. The DECODE study group. European diabetes epidemiology group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe;Borch‐Johnsen K, Neil A, Balkau B, et al. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria;Lancet.,1999

4. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin

5. Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current landscape and comprehensive management of glycemic variability in diabetic retinopathy;Journal of Translational Medicine;2024-07-29

2. Role of anagliptin, a dipeptidyl peptidase-4 inhibitor, in managing type 2 diabetes: A systematic review and meta-analysis;Medicine;2024-07-12